

*Copied to file, RHH,
Craig + Al; Taud
to Dennis + Anne*



150 Rednor - Chester Road, St. Davids, PA 19087 • (610) 902-5330 • FAX (610) 989-5724
E-mail: leem@labs.wyeth.com

Division of American Home Products Corporation

MARK L. LEE, Ph.D., MBA
Vice President
Worldwide Licensing

FILE COPY

Fax No.: (908) 739-0713

October 22, 1997

Dr. Robert H. Harris
President
FEDERAL RESEARCH CONSULTANTS
2139 Route 35
Holmdel, NJ 07733

Dear Dr. Harris:

I refer to your letter of September 15, 1997, to Mr. Larry McDermott of Wyeth-Ayerst Laboratories, on the subject of ADD-234037. Please be advised that he has retired from our Company.

We have reviewed the non-confidential information that you provided us on ADD-234037. While we recognize the intriguing potential of this compound for development as a useful therapeutic agent in epilepsy and stroke, I regret to say that it does not represent a good "fit" for us at this time. As you may know, we currently have a number of our own drugs in early clinical trials for both of these indications. In view of these prior commitments, I do not believe that we could devote the appropriate resources necessary to elaborate the potential of your drug. Of course, if our situation should change, we will not hesitate to contact you.

Thank you in any case for alerting us to this opportunity.

Sincerely,

Mark L. Lee

/rga

H:\WRD_DATA\MARKLEE\FRC.MLL